SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
- Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
- Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial delivery timelines, reduce site burden, and enhance U.S. enrollment.
- To date, this advancement is decreasing site-based data entry time, reducing manual labor, lowering monitoring costs, improving data quality, and accelerating clinical trial decision-making overall.
- “Working with SCRI to enhance U.S. enrollment and streamline clinical trial data collection is a tremendous opportunity to increase the diversity of clinical trial participants in the U.S. and accelerate clinical trial delivery timelines.